Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.52 |
| ▸ | LOX | P28300 | 1/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29769017 | 1.00 | LOXL2 (0.52) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL2259733 | 0.83 | LOXL2 (0.36) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL322475 | 0.78 | SYK (0.52) | LOXL2LOXNOTUMIDO1SYK | |
| SCHEMBL8764955 | 0.77 | SMARCA2 (0.33) | LOXL2SMARCA2SMARCA4CA2 | |
| SCHEMBL1765332 | 0.77 | LMNA (0.44) | — | |
| SCHEMBL30753318 | 0.77 | LOXL2 (0.33) | LOXL2LOXSYK | |
| SCHEMBL30328281 | 0.74 | LOXL2 (0.53) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL2642373 | 0.74 | LOXL2 (0.53) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL1643559 | 0.74 | LOXL2 (0.53) | LOXL2LOXSMARCA2SMARCA4NOTUM | |
| SCHEMBL2327508 | 0.74 | NOS3 (0.59) | LOXL2LOXSMARCA2SMARCA4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-04-02 | — | — | US | disclosed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260035375-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12509445-B2 | Herbicidally active 4-cyclopropyl-6-[4-(trifluormethyl)pyrazol-1-yl)]pyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-30 | — | — | US | disclosed |
| EP-4647429-A1 | PYRIDAZINONE HETEROCYCLIC COMPOUND MYOSIN II INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-12459952-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-12421193-B2 | GPR52 modulators and methods of use | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2003051846-A2 | SUBSTITUTED PHENYL DERIVATIVES | BAYER CROPSCIENCE GMBH (DE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003049737-A1 | CHEMICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| EP-1278722-A1 | ARYL AND HETEROARYL SULFONATES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | disclosed |
| EP-1230225-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2002050062-A2 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORPORATION (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001074763-A1 | ARYL AND HETEROARYL SULFONATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001032632-A2 | PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-05-10 | — | — | WO | disclosed |
| EP-0778267-A1 | SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622917-B2 | High-activity Wnt pathway inhibitor compound | WNT1, WNT3, WNT3A | LOXL2 3043/4885LOX 1976/4885SMARCA2 2107/4885 |
| US-12459952-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | LOXL2 454/4885LOX 1534/4885SMARCA2 2112/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | LOXL2 1507/4885LOX 695/4885SMARCA2 4139/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | LOXL2 137/4885LOX 153/4885SMARCA2 3356/4885 |
| US-12509445-B2 | Herbicidally active 4-cyclopropyl-6-[4-(trifluormethyl)pyrazol-1-yl)]pyrimidines | CBR3, CBR1, HAX1 | LOXL2 1979/4885LOX 1285/4885SMARCA2 4067/4885 |
| US-20260035375-A1 | TREM2 MODULATORS | MSR1, CSF1R, CX3CR1 | LOXL2 296/4885LOX 1032/4885SMARCA2 2738/4885 |
| US-20260092063-A1 | FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF | BRAF, NRAS, RAF1 | LOXL2 2477/4885LOX 2771/4885SMARCA2 757/4885 |
| US-12421193-B2 | GPR52 modulators and methods of use | GPR52, GPR68, GPR35 | LOXL2 1278/4885LOX 2631/4885SMARCA2 4337/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | LOXL2 4013/4885LOX 3956/4885SMARCA2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.